Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16746087 | 0.87 | XIAP (0.33) | XIAPBIRC2CYP11B1CYP11B2 | |
| SCHEMBL16746085 | 0.74 | ADRA2A (0.33) | — | |
| SCHEMBL16746146 | 0.73 | EPHX2 (0.44) | CYP11B1CYP11B2EPHX2 | |
| SCHEMBL16746138 | 0.72 | KIF11 (0.38) | BRD4 | |
| SCHEMBL16744233 | 0.70 | CYP11B1 (0.40) | XIAPBIRC2CYP11B1CYP11B2 | |
| SCHEMBL16746147 | 0.70 | MMP12 (0.40) | — | |
| SCHEMBL16746145 | 0.70 | EPHX2 (0.41) | EPHX2 | |
| SCHEMBL3860722 | 0.69 | GABRA1 (0.32) | — | |
| SCHEMBL16750259 | 0.69 | — | — | |
| SCHEMBL16746089 | 0.69 | NPC1 (0.37) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148372-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | XIAP 1325/4885BIRC2 123/4885CYP11B1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.